Innovent Biologics announces the appointment of Dr. Zhang as global chief business officer (CBO)

san francisco and Suzhou China, April 30, 2024 /PRNewswire/—— Innovent Biopharmaceutical Co., Ltd. Innovent Biologics Limited (“Innovent Biologics”) (HKSE: 01801) is a world-wide company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmic and other major diseases. biopharmaceutical company, today announced the appointment. Samuel Zhang Serves as its global chief commercial officer (CBO). In this role, Dr. Zhang Will be responsible for the global strategy and business development of Innovent Biologics, and will report to Dr. Yu Dehua, founder, chairman and CEO of Innovent Biologics.

Dr. Zhang He has more than 20 years of industry experience across the entire spectrum of pharmaceutical research, development and commercialization. He has a proven track record of success in identifying emerging industry trends and promising assets early, supporting major R&D decisions for both large biopharmaceutical and smaller biotech companies, and designing science-based products. quickly Develop market development strategies to address large unmet medical needs, realize commercial value in competitive markets, and facilitate large strategic transactions.

Before joining Innovent Biotech, Dr. Zhang Served as CBO Grace Biotech Co., Ltd. and New immune technology. recent, Dr. Zhang Led the global partner discussion for Gracell Biotechnology and finally reached an agreement $1.2B Acquired by AstraZeneca (NASDAQ: ). He also held positions of increasing responsibility at Eli Lilly (NYSE: ), Pfizer (New York Stock Exchange:), Bristol-Myers Squibb (NYSE: ), Novartis (VI:) and Merus (NASDAQ: ).

Dr. Zhang Holds a Ph.D.PhD in Molecular Biology Columbia UniversityMBA degree Wharton Business School of University of Pennsylvaniaand received a B.S. Peking University.

“We warmly welcome Dr. Zhang Joined Innovent Biologics as CBO. Dr. Zhang Proven experience and demonstrated leadership in business development. We firmly believe that his joining will help Innovent to significantly enhance its global strategy and business development capabilities and further accelerate our globalization. PhD. MaikeyuFounder, Chairman and CEO of Innovent Biologics.

“Innovent Biologics has achieved great success since its establishment 12 years ago and has always paid close attention to corporate development strategies and global partnerships.” PhD. Samuel Zhang“I am delighted to join Innovent at this special time to help build this strong foundation, pioneer new science, and collaborate with multinational companies to develop breakthrough medicines that benefit patients in urgent need around the world.”

About Innovent Biologics

Innovent Biologics is a leading biopharmaceutical company founded in 2011 with a mission to make high-quality biologics affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines for some of the most challenging diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and ocular diseases. Innovent Biologics has launched 10 products into the market. The company has three new drug applications under regulatory review, five assets in Phase III or pivotal clinical trials, and 18 molecules in early clinical stages. Innovent partners with more than 30 global healthcare companies, including Eli Lilly and Company, Sanofi (NASDAQ: ), Incyte (NASDAQ: ), AdimabuLG Chem and MD Anderson Cancer Center.

Innovent Biologics adheres to the motto of “Integrity based, action wins”, maintains the highest industry practice standards, jointly promotes the development of the biopharmaceutical industry, and makes first-class drugs widely available. For more information, visit or follow Innovent on Facebook (NASDAQ: ) and LinkedIn.


Tyvyt® (sintilimab injection) is not a product approved by China USA.

BYVASDA® (bevacizumab biosimilar injection), SULINNO® and HALPRYZA® (rituximab biosimilar injection) have not been approved USA.

Tyvyt® (sintilimab injection, Innovent)

BYVASDA® (bevacizumab biosimilar injection, Innovent)

HALPRYZA® (rituximab biosimilar injection, Innovent)

SULINNO® (adalimumab biosimilar injection, Innovent)

Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in mainland China. Hongkong, Macao and Taiwan.

CYRAMZA ® (ramucirumab, Eli Lilly and Company). Cyramza ® was discovered by Eli Lilly and Company and licensed to Innovent for commercialization in mainland China.

Retsevmo® (selpercatinib, Eli Lilly and Company). Retsevmo ® was discovered by Eli Lilly and Company and licensed to Innovent for commercialization in mainland China.

Disclaimer: Innovent does not recommend the use of any unapproved drugs/indications.

forward-looking statements

This press release may contain certain forward-looking statements that are inherently subject to significant risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “anticipate,” “intend” and similar expressions when used in connection with Innovent are intended to identify certain such forward-looking statements. Innovent does not intend to regularly update these forward-looking statements.

These forward-looking statements are based on Innovent's management's current beliefs, assumptions, expectations, estimates, projections and understandings of future events at the time the statements are made. These statements are not guarantees of future development and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Therefore, actual results may differ materially from the information contained in the forward-looking statements due to future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

Innovent Biologics, its directors and employees disclaim (a) any obligation to correct or update forward-looking statements contained in this website; (b) if any forward-looking statement fails to materialize or proves to be incorrect; We do not assume any responsibility.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *